Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - Chelsea Therapeutics International, Ltd. | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 26, 2011
CHELSEA THERAPEUTICS
INTERNATIONAL, LTD.
(Exact name of registrant as specified in its charter)
Delaware | 000-51462 | 20-3174202 | ||
(State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer ID Number) |
3530 Toringdon Way, Suite 200, Charlotte, North Carolina 28277 | ||
(Address of principal executive offices) (Zip Code) |
Registrants telephone number, including area code (704) 341-1516
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other Events.
On July 26, 2011, Chelsea Therapeutics International, Ltd. issued a press release announcing preliminary data from an exploratory Phase II study of droxidopa in adult attention deficit hyperactivity disorder, or ADHD. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) | Exhibits |
Exhibit |
Description | |
99.1 | Press release dated July 26, 2011. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHELSEA THERAPEUTICS INTERNATIONAL, LTD. | ||||
Date: July 26, 2011 | /s/ J. Nick Riehle | |||
J. Nick Riehle, Chief Financial Officer |
3